In the other areas of the pharma chain in Digital Data we have use cases like:
- Logistics and transportation: We now have several nearly fully automated, remote-monitored, insight-generating digital factories and are improving our supply chain using predictive AI.
- Commercial and marketing: We are deploying direct-to-consumer ecommerce platforms and have deployed a new and improved customer relationship management system that improves our interactions with healthcare professionals.
What are some of the questions you are helping to answer for the clinical team?
One of the common questions we try to answer is, which segment of the population responds better or worse to a particular drug? This is specifically tailored to Randomized Clinical Trials, where we are trying to cross-reference Real World Evidence and use previously existing Randomized Clinical Trials data sources to observe how a drug may perform in different population segments. All of this serves to increase the probability of success to have a drug with high efficacy and safety.
Another common question we try to answer is, how can we take a drug currently in market and find new indications currently not treated with the drug that may benefit from its use. This positioning of our portfolio allows our drugs to provide potentially life-changing treatments to a wider population.
There are a lot of existing data on previous drugs that came out of Sanofi’s pipeline. We are examining whether we can use these massive troves of data to help us train AI algorithms that can answer the previously mentioned problems.
Why should Sanofi focus on Data and Artificial Intelligence?
While the healthcare industry is slow to adapt, tech giants are moving into the space quickly and start-ups are increasingly disrupting the well-established beliefs, processes and business models. Whether we’re shortening development times for our R&D teams or providing new digital interfaces for patients worldwide, it’s clear that embracing digital is key for us to chase the miracles of science to improve people’s lives. Sanofi must catch up to its peers in certain areas, and leapfrog them in others, in order to remain relevant. Digital will be a key catalyst in this company-wide modernization.
In the first phase of our transformation, we are modernizing our foundation while also creating value for the business. Our modernization is focused on cloud migration, scalable, democratized and AI-driven data solutions, and a more efficient infrastructure. In parallel, we are already creating value for the business across R&D, Manufacturing & Supply, and Commercial through priority initiatives agreed upon by the ExCom.
In the second phase of our transformation, Digital will accelerate the value creation across our GBUs and GFs, create completely new digital businesses, and move us to an AI-driven decision-making organization.
The advantage here would be a more efficient, time saving, and objective systems that can rapidly answer business questions and provide future insights.
